News & Updates

Show Multimedia Only

Vaginal gel shows promise in vulvovaginal atrophy

12 Mar 2021

A novel vaginal gel appears beneficial in the treatment of postmenopausal women with vulvovaginal atrophy, relieving symptoms and improving sexual function with good overall compliance, according to a study.

Vaginal gel shows promise in vulvovaginal atrophy

12 Mar 2021

Penicillin skin testing – how safe in pregnant women?

12 Mar 2021 by

Penicillin skin testing in pregnant women is safe both for the mum and the baby, experts assure at AAAAI 2021.

Penicillin skin testing – how safe in pregnant women?

12 Mar 2021

Apalutamide added on to abiraterone acetate, prednisone extends rPFS in mCRPC

12 Mar 2021 by

Adding apalutamide (APA) to abiraterone acetate and prednisone (AAP) significantly extends radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with AAP only, according to the final analysis of the ACIS* trial presented at ASCO GU 2021.

Apalutamide added on to abiraterone acetate, prednisone extends rPFS in mCRPC

12 Mar 2021

Extended follow-up of KEYNOTE-240 shows pembrolizumab maintains OS, PFS in advanced HCC

12 Mar 2021 by

Longer-term follow-up after the final analysis of the KEYNOTE-240* trial showed that improvements in overall survival (OS) and progression-free survival (PFS) with pembrolizumab were maintained in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib, according to updated results of the trial presented at ASCO GI 2021.

Extended follow-up of KEYNOTE-240 shows pembrolizumab maintains OS, PFS in advanced HCC

12 Mar 2021

Adding bemarituzumab to chemo may up survival in advanced FGFR2b+, HER2- gastric cancer

11 Mar 2021 by

Adding bemarituzumab to mFOLFOX6 significantly improved survival outcomes and response rate compared with mFOLFOX6 alone in patients FGFR2b-positive, HER2-negative gastric cancer, according to the FIGHT study presented at the 2021 ASCO GI Cancer Symposium.

Adding bemarituzumab to chemo may up survival in advanced FGFR2b+, HER2- gastric cancer

11 Mar 2021

Efficacy, safety both essential in choosing atypical antipsychotic treatments

11 Mar 2021

A recent study of beliefs and preferences by psychiatrists and psychiatric pharmacists has found that efficacy and safety are equally important when choosing atypical antipsychotic treatments in patients with schizophrenia and bipolar disorders. In addition, they deem that formulary restrictions affect treatment choice and outcomes.

Efficacy, safety both essential in choosing atypical antipsychotic treatments

11 Mar 2021

VTE recurrence similar in patients on DOACs weighing ≥120 vs <120 kg

11 Mar 2021

The recurrence of venous thromboembolism (VTE) is comparable in patients on direct-acting oral anticoagulants (DOACs) weighing ≥120 and those weighing <120 kg, with few events in either group, a recent study has shown.

VTE recurrence similar in patients on DOACs weighing ≥120 vs <120 kg

11 Mar 2021

Antispike nMAb combo reduces viral load in COVID-19 outpatients

11 Mar 2021 by

A combination of two potent antispike neutralizing monoclonal antibodies (nMAbs) – bamlanivimab and etesevimab – significantly reduced viral load in nonhospitalized individuals with mild-to-moderate COVID-19, the phase II/III BLAZE-1* trial has shown.

Antispike nMAb combo reduces viral load in COVID-19 outpatients

11 Mar 2021

GI cancer patients could continue therapy during COVID-19 pandemic

10 Mar 2021 by

Results of a single-centre study in the UK have suggested that patients receiving systemic anticancer therapy for gastrointestinal (GI) cancers could continue their treatment during the COVID-19 pandemic.

GI cancer patients could continue therapy during COVID-19 pandemic

10 Mar 2021

Extended-release viloxazine for ADHD in kids scores high in phase III trial

10 Mar 2021 by

The investigational attention-deficit/hyperactivity disorder (ADHD) medication viloxazine extended-release, known as SPN-812, rapidly reduces symptoms in school-aged children with a tolerable safety profile, as shown in the results of a phase III trial.

Extended-release viloxazine for ADHD in kids scores high in phase III trial

10 Mar 2021

News & Updates

Filter by Specialty:

Specialty:

Vaginal gel shows promise in vulvovaginal atrophy

Vaginal gel shows promise in vulvovaginal atrophy

Penicillin skin testing – how safe in pregnant women?

Penicillin skin testing – how safe in pregnant women?

Apalutamide added on to abiraterone acetate, prednisone extends rPFS in mCRPC

Apalutamide added on to abiraterone acetate, prednisone extends rPFS in mCRPC

Extended follow-up of KEYNOTE-240 shows pembrolizumab maintains OS, PFS in advanced HCC

Extended follow-up of KEYNOTE-240 shows pembrolizumab maintains OS, PFS in advanced HCC

Adding bemarituzumab to chemo may up survival in advanced FGFR2b+, HER2- gastric cancer

Adding bemarituzumab to chemo may up survival in advanced FGFR2b+, HER2- gastric cancer

Efficacy, safety both essential in choosing atypical antipsychotic treatments

Efficacy, safety both essential in choosing atypical antipsychotic treatments

VTE recurrence similar in patients on DOACs weighing ≥120 vs <120 kg

VTE recurrence similar in patients on DOACs weighing ≥120 vs <120 kg

Antispike nMAb combo reduces viral load in COVID-19 outpatients

Antispike nMAb combo reduces viral load in COVID-19 outpatients

GI cancer patients could continue therapy during COVID-19 pandemic

GI cancer patients could continue therapy during COVID-19 pandemic

Extended-release viloxazine for ADHD in kids scores high in phase III trial

Extended-release viloxazine for ADHD in kids scores high in phase III trial